Hydrocortisone-associated death and hospital length of stay in patients with sepsis: A retrospective cohort of large-scale clinical care data

• Published in: Biomedicine & pharmacotherapy Vol. 170; p. 115961
• Main Authors: Li, Mohan, Noordam, Raymond, Winter, Elizabeth M., van Meurs, Matijs, Bouma, Hjalmar R., Arbous, M. Sesmu, Rensen, Patrick C.N., Kooijman, Sander
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01-01-2024; Elsevier
• Subjects: Hydrocortisone; Pharmacoepidemiology; Prognosis; Propensity score matching; Sepsis; Pharmacoepidemiology; Propensity score matching; Sepsis; Prognosis; Hydrocortisone
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2023.115961

Sepsis is one of the leading causes of morbidity and mortality worldwide with approximately 50 million annual cases. There is ongoing debate on the clinical benefit of hydrocortisone in the prevention of death in septic patients. Here we evaluated the association between hydrocortisone treatment and mortality in patients diagnosed with sepsis in a large-scale clinical dataset.
Data from patients between 2008 and 2019 were extracted from the retrospective Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Patients who received hydrocortisone after diagnosis were matched using propensity-score matching with patients who did not, to balance confounding (by indication and contraindication) factors between the groups. 90-day mortality and survivors’ length of hospital stay was compared between patients who did or did not receive hydrocortisone.
A total of 31,749 septic patients were included in the study (mean age: 67, men: 57.3%, in-hospital mortality: 15.6%). 90-day mortality was higher among the 1802 patients receiving hydrocortisone when compared with the 6348 matched non-users (hazard ratio: 1.35, 95% CI: 1.24–1.47). Hydrocortisone treatment was also associated with increased in-hospital mortality (40.9% vs. 27.6%, p < 0.0001) and prolonged hospital stay in those who survived until discharge (median 12.6 days vs. 10.8 days, p < 0.0001). Stratification for age, gender, ethnicity, occurrence of septic shock, and the need for vasopressor drug administration such as (nor)epinephrine did not reveal sub-population(s) benefiting of hydrocortisone use.
Hydrocortisone treatment is associated with increased risk of death as well as prolonged hospital stay in septic patients. Although residual confounding (by indication) cannot be ruled out completely due to the observational nature of the study, the present study suggests clinical implication of hydrocortisone use in patients with sepsis.
[Display omitted]
•Hydrocortisone use is not associated with improved sepsis-related outcomes.•Hydrocortisone use is related with longer ICU stay.•Prescription of hydrocortisone on septic patients should be considered more carefully.